Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed

Ítems similars

• Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
  per: Milojkovic, Dragana, et al.
  Publicat: (2010)
• Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients
  per: Milojkovic, Dragana, et al.
  Publicat: (2012)
• Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
  per: Ibrahim, Amr R., et al.
  Publicat: (2010)
• Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy
  per: Neelakantan, Pratap, et al.
  Publicat: (2012)
• Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response
  per: Kuwabara, Aya, et al.
  Publicat: (2010)